All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
An FDA request for more data doesn’t disqualify patent claims stemming from the research, the U.S. Court of Appeals for the Federal Circuit ruled Thursday in Cumberland Pharmaceuticals Inc. v. Mylan Inc.